Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Strong Trading Volume – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw unusually-high trading volume on Friday . Approximately 20,050 shares changed hands during mid-day trading, an increase of 358% from the previous session’s volume of 4,378 shares.The stock last traded at $46.25 and had previously closed at $46.93.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ZLDPF. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3.21 billion, a P/E ratio of 3.30 and a beta of 0.88. The business’s fifty day moving average is $52.19 and its 200 day moving average is $66.43.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. The company had revenue of $10.79 million during the quarter, compared to analyst estimates of $19.69 million. As a group, analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.